BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/4/2026 3:47:11 AM | Browse: 2 | Download: 4
 |
Received |
|
2026-06-22 02:02 |
|
Peer-Review Started |
|
2026-06-22 02:02 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-07-21 03:45 |
|
Revised |
|
2026-07-27 02:38 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-09-11 02:52 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-09-11 09:25 |
|
Articles in Press |
|
2026-09-11 09:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-10-30 09:04 |
|
Publish the Manuscript Online |
|
2026-11-04 03:47 |
| ISSN |
2220-6132 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Genetics & Heredity |
| Manuscript Type |
Review |
| Article Title |
Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Lucas D Feliciano, João P C Freire, Caio F Lopes, Pedro H M Lima, Juan M C Costa and Fabrício Freire de Melo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fabrício Freire de Melo, PhD, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros 58, Quadra 17, Lote 58, Vitória da Conquista 45029-072, Bahia, Brazil. freiremeloufba@gmail.com |
| Key Words |
Lipoprotein(a); Residual cardiovascular risk; Gene silencing; Small interfering RNA; Antisense oligonucleotides |
| Core Tip |
Lipoprotein(a) [Lp(a)] is increasingly recognized as an important genetically determined cardiovascular risk factor with proatherogenic, proinflammatory, and prothrombotic properties that contribute to atherosclerotic cardiovascular disease and calcific aortic valve disease. This review discusses the molecular structure, genetic determinants, pathogenic mechanisms, and clinical relevance of Lp(a), as well as current challenges in laboratory assessment and emerging targeted therapies. Advances in understanding and treating elevated Lp(a) may improve cardiovascular risk stratification and open new perspectives for personalized preventive cardiology. |
| Publish Date |
2026-11-04 03:47 |
| Citation |
Feliciano LD, Freire JPC, Lopes CF, Lima PHM, Costa JMC, de Melo FF. Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing. World J Transl Med 2026; 12(4): 124606
|
| URL |
https://www.wjgnet.com/2220-6132/full/v12/i4/124606.htm |
| DOI |
https://doi.org/10.5528/wjtm.124606 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
